Respiratory Polygraphy Patterns and Risk of Recurrent Cardiovascular Events in Patients With Acute Coronary Syndrome

Andrea Zapater1,2,†, Geoffroy Solelhac3,‡‡, Alicia Sánchez-de-la-Torre4,4, Esther Gracia-Lavedan5,6, Ivan David Benítez7,8, Gerard Torres9,10, Jordi De Batlle4,10, José Haba-Rubio5, Mathieu Berger9, Jorge Abad5, Joaquín Duran-Cantolla2,6, Amaia Urrutia7, Olga Mediano2,8, María José Masdeu4,9, Estrella Ordx-Cardaño5, Juan Fernando Masa2,11, Mónica De la Peña12, Mercé Mayos2,13, Ramón Coloma14, Josep Maria Montserrat2,15, Eusebi Chiner10,15, Olga Mínguez2, Lydia Pascual7, Anunciación Cortijo10, Dolores Martínez14, Mireia Dalmases2,15, Chi-Hang Lee17,18, R. Doug McEvoy19, Ferran Barbé2,2, Raphael Heinzner2,15 and Manuel Sánchez-de-la-Torre1,2,20 and Spanish Sleep Network

Introduction: Obstructive sleep apnea (OSA) severity is based on the apnea-hypopnea index (AHI). The AHI is a simplistic measure that is inadequate for capturing disease severity and its consequences in cardiovascular diseases (CVDs). Deleterious effects of OSA have been suggested to influence the prognosis of specific endotypes of patients with acute coronary syndrome (ACS). We aim to identify respiratory polygraphy (RP) patterns that contribute to identifying the risk of recurrent cardiovascular events in patients with ACS.

Methods: Post hoc analysis of the ISAACC study, including 723 patients admitted for a first ACS (NCT01335087) in which RP was performed. To identify specific RP patterns, a principal component analysis (PCA) was performed using six RP parameters: AHI, oxygen desaturation index, mean and minimum oxygen saturation (SaO2), average duration of events and percentage of time with SaO2 < 90%. An independent HypnoLaus population-based cohort was used to validate the RP components.
INTRODUCTION

Cardiovascular diseases (CVDs) are one of the leading causes of death worldwide, and more than half are consequences of coronary heart disease, which is often manifested for the first time as acute coronary syndrome (ACS). Ranging from unstable angina to myocardial infarction, ACS is the main cause of morbidity and mortality worldwide (1, 2).

Obstructive sleep apnea (OSA) is a prevalent and chronic disease that affects more than 20% of the adult population (3) and is caused by the collapse of the upper airway during sleep, which leads to transient asphyxia. These events lead to brain arousal, intermittent hypoxemia, poor quality of life and metabolic disturbances. OSA is considered an important public health problem and is largely associated with cardiovascular outcomes (4, 5). In fact, basic, epidemiological and clinical research suggests a role of OSA in the initiation and/or progression of several CVDs (6). Observational studies have suggested that OSA is an independent risk factor for cardiovascular morbidity and mortality (7). However, there is a lack of a dose-response relationship between the severity of the disease [expressed by the apnea hypopnea index (AHI)] and cardiovascular risk, and some studies did not find an association between OSA and cardiovascular risk (8, 9). In the ISAAC study, a randomized controlled trial to evaluate the effect of intervention with continuous positive airway pressure (CPAP) treatment on the risk of recurrent cardiovascular events in patients with ACS, OSA was not associated with a worse cardiovascular risk prognosis in patients with ACS (8). A post hoc study from the ISAACC cohort, component 2 was associated with an increased risk of recurrent cardiovascular events in the third tertile with an adjusted hazard ratio (95% CI) of 2.44 (1.07 to 5.56; p-value = 0.03) compared to first tertile. For component 1, no significant association was found for the risk of recurrent cardiovascular events.

Conclusion: A RP component, mainly characterized by intermittent hypoxemia, is associated with a high risk of recurrent cardiovascular events in patients without previous CVD who have suffered a first ACS.

Keywords: acute coronary syndrome, cardiovascular disease, obstructive sleep apnea, precision medicine, respiratory polygraphy

Results: From the ISAACC study, PCA showed that two RP components accounted for 70% of the variance in the RP data. These components were validated in the HypnoLaus cohort, with two similar RP components that explained 71.3% of the variance in the RP data. The first component (component 1) was mainly characterized by low mean SaO₂ and obstructive respiratory events with severe desaturation, and the second component (component 2) was characterized by high mean SaO₂ and long-duration obstructive respiratory events without severe desaturation. In the ISAACC cohort, component 2 was associated with an increased risk of recurrent cardiovascular events in the third tertile with an adjusted hazard ratio (95% CI) of 2.44 (1.07 to 5.56; p-value = 0.03) compared to first tertile. For component 1, no significant association was found for the risk of recurrent cardiovascular events.

Available evidence supports that the indicators of cardiovascular risk in patients with OSA, mainly based on AHI, are insufficient. In the present study, we aimed to evaluate the RP patterns that could contribute to identifying the risk of
MATERIALS AND METHODS

Study Design
This is an ancillary study of the ISAACC (Impact of Sleep Apnea syndrome in the evolution of ACS. Effect of intervention with CPAP) study, a multicenter, open-label, parallel, prospective, randomized, controlled trial (registered trial NCT01335087). Full details of the ISAACC study’s methods, including inclusion and exclusion criteria, have been previously reported (14). Briefly, eligible patients were ≥18 years old, had been admitted for ACS to coronary care units or cardiology hospitalization ward at 15 hospitals in Spain and had an Epworth Sleepiness Scale score of ≤10 (i.e., patients without excessive daytime sleepiness or non-sleepy). Eligible patients underwent RP (Emblettta, ResMed, Bella Vista, NSW, Australia) during the first 24–72 h after admission to evaluate the presence of OSA (14). For the current post hoc study, we analyzed the data from 723 ISAACC patients with a first ACS and without CVD (Figure 1) and in whom a deleterious effect of OSA was observed (13).

Acute coronary syndrome was defined as the acute presentation of coronary disease with or without ST elevation infarction, unstable angina, or type 1 myocardial infarction.

The ethics committee of each participating center approved the study (approval number in the coordinating center: 2010-852) and patients provided written informed consent.

The RP components in the ISAACC cohort was externally validated in the HypnoLaus population-based cohort (3), a nested-study of CoLaus/PsyCoLaus (15, 16). This study was designed to assess the prevalence of sleep-disordered breathing in a general population aged 35–75 years who were selected at random and were enrolled in the study.

Procedures and Outcomes

ISAACC Cohort
Questionnaires to record demographic and anthropometric characteristics, medical history and usual pharmacological treatment were administered the day before the sleep study along with questionnaires associated with quality of life (EuroQol-5D questionnaire) and the degree of daytime sleepiness (Epworth Sleepiness Scale test). All patients were evaluated at baseline and 1 month, 3 months, 6 months, 12 months, 18 months, 24 months, 30 months, 36 months, and annually thereafter. All patients were monitored and followed up for a minimum of 1 year. At each visit, sociodemographic and anthropometric variables previously related to increased cardiovascular risk were recorded. Each follow-up visit included assessments of the rate of a composite of cardiovascular events [cardiovascular death or non-fatal events (acute myocardial infarction, non-fatal stroke, hospital admission for heart failure and new hospitalizations for unstable angina or transient ischemic attack)].

For the present study, we explored RP parameters to identify specific components, including the AHI, oxygen desaturation index (ODI, >4%), mean and minimum oxygen saturation (SaO2), average duration of events and percentage of time with SaO2 < 90%. We explored the contribution of RP components to the risk of recurrent cardiovascular events.

The cardiovascular risk variables explored were age, sex, current cigarette smoking, current alcohol consumption, obesity, hypertension, previous cerebrovascular disease, diabetes mellitus, and dyslipidemia (low-density lipoprotein cholesterol ≥100 mg/dL or the use of lipid-lowering drugs). Moreover, on the basis of cardiovascular risk prediction models...
(17, 18), we explored the following other cardiovascular variables: antihypertensive drugs, antiplatelet, and antithrombotic drugs, heart rate, systolic blood pressure, initial serum creatinine, stents implanted, no in-hospital percutaneous coronary intervention troponin and mean SaO2.

**HypnoLaus Cohort**

Participants underwent full polysomnography at home. Details of the sampling and procedure methodologies have been described elsewhere (3, 15). For the current study, we analyzed the data from 1941 HypnoLaus patients. The ethics committee of the University of Lausanne approved the CoLaus/PsyCoLaus cohort study and the HypnoLaus Sleep Cohort study. We obtained written informed consent from all participants.

**Statistical Analysis**

The main characteristics were described using medians (25th percentile and 75th percentile) or percentages. The P value for trend was evaluated using Spearman’s rank correlation coefficient when data were continuous and non-normally distributed and the chi-square test for trend when they were categorical (19).

Principal component analysis (PCA) was used to avoid collinearity between the RP parameters to identify relational patterns that reflect sleep apnea patterns. Six RP standardized parameters previously mentioned were used in the PCA. RP parameters that were not normally distributed were log-transformed and then included in the PCA (ODI and AHI). The magnitude of the eigenvalues > 1 (20) and variance explained by each component were used to determine the number of principal components to select. The components are described by the correlations with each RP parameter included in the PCA. Selected components from the PCA were grouped into tertiles and included in the model to explore the association with the primary composite endpoint. Cox proportional regression models adjusted by the predictors mentioned in the previous section were used. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were reported. The proportional hazard assumption was checked in all models. Discrimination was assessed using the C-statistic (21).

Statistical analyses were conducted using R, version 3.6 (22). Two-sided p-values were reported, and statistical significance was set at 0.05.

**RESULTS**

**Patient Characteristics**

**ISAACC Cohort**

From a total of 1,851 patients with ACS enrolled in the ISAACC cohort, we included 948 patients without CPAP treatment and without previous CVD. Finally, 723 patients with available data for the variables explored were included in the present study (Figure 1). The median age of the patients was 58 years, and 81.6% were males (Table 1). The patients were followed for a median of 3.33 (interquartile range: 3.72) years. Excluded patients had sociodemographic and clinical characteristics similar to those of the patients included in the analysis (Supplementary Table 1).

A total of 11.5% of the patients had recurrent cardiovascular events during follow-up (Supplementary Table 2).

**HypnoLaus Cohort**

The external validation cohort was 2,168 individuals from the HypnoLaus population-based cohort. Finally, 1941 individuals were selected without previous CVD and available data. The median age was 56.9 years, 47% were males, and the median AHI was 9.8 events per hour (Supplementary Table 3). The mean time of follow-up (or CV event) was 4.25 (standard deviation: 1.77) years.

**Identification of Respiratory Polygraphy Components**

Principal component analysis was performed using the six RP parameters: AHI, ODI, mean and minimum SaO2, average duration of events and percentage of time with SaO2 <90%. The first two components were selected to characterize the RP patterns. In the ISAACC study, these two components, which contributed significantly to explaining the relationships among the six RP parameters (eigenvalues >1), accounted for 70% of the variability of the RP data (Supplementary Table 4). The first component (Component 1) was highly correlated with the AHI, ODI and percentage of time with SaO2 <90% and inversely correlated with the mean and minimum SaO2. Component 1 accounted for 42.2% of the variability of the RP data. The second component (Component 2) was highly correlated with the AHI, ODI, mean SaO2, and average duration of events and inversely correlated with the percentage of time with SaO2 <90% (Figure 2A). Component 2 accounted for 26.6% of the variability of the RP data. Whereas the mean and minimum SaO2 were negatively correlated in component 1, in the component 2 mean SaO2 was positively correlated. Additionally, the correlation of duration obstructive respiratory events was higher in component 2. Table 2 shows the description of the RP parameters by tertiles of each RP component identified and selected (components 1 and 2).

From the validation, the PCA was repeated in the HypnoLaus cohort using the same six RP parameters explored in the ISAACC cohort, and the first two components explained 71.3% of the variance of the RP data (Supplementary Table 5). Both components presented a high degree of similarity to those identified in the ISAACC cohort (Figure 2B). The RP parameters were described by tertiles of the selected component for the HypnoLaus cohort (Supplementary Table 6).

**Respiratory Polygraphy Component Distribution**

ISAACC patients were characterized using sociodemographic and clinical characteristics by tertiles of the two RP components (Supplementary Table 7). Patients with high adherence in component 1 had more comorbidities, as the third tertile showed a greater proportion of patients with obesity, hypertension and diabetes. Similar characteristics were shown by tertiles of component 2.
TABLE 1 | Baseline characteristics of patients from the ISAACC cohort.

| Variable                              | All          | No recurrent CVE | Recurrent CVE | P value |
|---------------------------------------|--------------|------------------|---------------|---------|
|                                      | (N = 723)    | (N = 640)        | (N = 83)      |         |
| Sex                                   |              |                  |               | 0.203   |
| Female                                | 133 (18.4%)  | 113 (17.7%)      | 20 (24.1%)    |         |
| Male                                  | 590 (81.6%)  | 527 (82.3%)      | 63 (75.9%)    |         |
| Anthropometric measures               |              |                  |               |         |
| Age, years                            | 58.0         | 58.0             | 58.0          | 0.426   |
| Body mass, kg · m⁻²                   | [51.0; 66.0] | [51.0; 66.0]     | [52.5; 66.5]  |         |
| Waist-to-hip ratio                    | 0.98         | 0.98             | 0.99          | 0.435   |
| [0.94; 1.02]                          | [0.94; 1.02] | [0.95; 1.03]     |               |         |
| Neck circumference, cm                | 40.0         | 40.0             | 40.0          | 0.662   |
| [38.0; 43.0]                          | [38.0; 43.0] | [38.0; 42.0]     |               |         |
| Lifestyle risk factors                |              |                  |               | 0.838   |
| Smoking                               |              |                  |               |         |
| Never                                 | 189 (26.1%)  | 166 (25.9%)      | 23 (27.7%)    |         |
| Former                                | 166 (23.0%)  | 149 (23.3%)      | 17 (20.5%)    |         |
| Current                               | 368 (50.9%)  | 325 (50.8%)      | 43 (51.8%)    |         |
| Drinking                              |              |                  |               | 0.168   |
| No                                    | 534 (73.9%)  | 467 (73.0%)      | 67 (80.7%)    |         |
| Yes                                   | 189 (26.1%)  | 173 (27.0%)      | 16 (19.3%)    |         |
| Sleep parameters                      |              |                  |               |         |
| AHl, events per h                     | 16.5         | 15.9             | 20.2          | 0.016   |
| [7.00; 33.3]                          | [6.70; 33.0] | [11.1; 37.1]     |               |         |
| ODI > 4%, per h                       | 14.0         | 13.9             | 16.7          | 0.061   |
| [5.25; 29.9]                          | [5.00; 29.3] | [8.75; 34.9]     |               |         |
| Mean SaO₂, %                          | 93.1         | 93.1             | 93.3          | 0.785   |
| [92.0; 94.4]                          | [92.0; 94.3] | [92.0; 94.5]     |               |         |
| Minimum                               | 86.0         | 86.0             | 86.0          | 0.351   |
| SaO₂, %                               | [81.0; 88.0] | [81.0; 88.0]     | [82.0; 89.0]  |         |
| Time with PaO₂ < 90%, %               | 1.05         | 1.05             | 0.60          | 0.512   |
| [0.10; 7.25]                          | [0.10; 7.35] | [0.00; 6.80]     |               |         |
| Average duration of events, sec      | 20.0         | 20.0             | 19.0          | 0.464   |
| [17.0; 23.0]                          | [17.0; 23.0] | [17.0; 22.5]     |               |         |
| Epworth sleepiness scale              | 5.00         | 5.00             | 5.00          | 0.152   |
| [3.00; 7.00]                          | [3.00; 7.00] | [3.00; 7.00]     |               |         |
| Medical history                       |              |                  |               |         |
| Hypertension                          | 325 (45.0%)  | 278 (43.4%)      | 47 (56.6%)    | 0.031   |
| Diabetes mellitus                     | 141 (19.5%)  | 112 (17.5%)      | 29 (34.9%)    | <0.001  |
| Dyslipidemia                          | 596 (82.4%)  | 530 (82.8%)      | 66 (79.5%)    | 0.556   |
| Cerebrovascular disease               | 16 (2.21%)   | 12 (1.88%)       | 4 (4.82%)     | 0.100   |
| Chronic pneumonia                     | 35 (4.84%)   | 32 (5.00%)       | 3 (3.61%)     | 0.787   |
| Neurological disease                  | 31 (4.29%)   | 26 (4.06%)       | 5 (6.02%)     | 0.387   |
| Severity of ACS                       |              |                  |               | 0.331   |
| Mild                                  | 653 (90.3%)  | 581 (90.8%)      | 72 (86.7%)    |         |
| Severe                                | 70 (9.68%)   | 59 (9.22%)       | 11 (13.3%)    |         |

(Continued)

TABLE 1 | (Continued) | Baseline characteristics of patients from the ISAACC cohort.

| Variable                              | All          | No recurrent CVE | Recurrent CVE | P value |
|---------------------------------------|--------------|------------------|---------------|---------|
|                                      | (N = 723)    | (N = 640)        | (N = 83)      |         |
| Medication                            |              |                  |               |         |
| Antihypertensive drug                 | 293 (40.5%)  | 251 (39.2%)      | 42 (50.6%)    | 0.062   |
| Lipid-lowering drug                   | 188 (26.0%)  | 161 (25.2%)      | 27 (32.5%)    | 0.191   |
| Antidiabetic oral medication          | 113 (15.6%)  | 87 (13.6%)       | 26 (31.3%)    | <0.001  |
| Insulin                               | 26 (3.60%)   | 21 (3.28%)       | 5 (6.02%)     | 0.207   |
| Antiplatelet and antithrombotic drugs | 69 (9.54%)   | 45 (7.03%)       | 24 (28.9%)    | <0.001  |
| Cardiovascular variables              |              |                  |               |         |
| Heart rate, bpm                       | 70.0         | 63.5; 80.0       | 73.0          | 0.125   |
| Systolic blood pressure, mm Hg        | 120 [110; 133]| 120 [110; 133]  | 120 [110; 130]| 0.608   |
| Creatinine, mg/dL                     | 0.85         | 0.73; 0.99       | 0.88          | 0.131   |
| Stents                                | 652 (90.2%)  | 575 (89.8%)      | 77 (92.8%)    | 0.518   |
| Ultrasound implantation               |              |                  |               |         |
| Peak troponin, quartiles              |              |                  |               | 0.070   |
| Non-Q-wave AMI                        | 299 (41.4%)  | 264 (41.2%)      | 35 (42.2%)    |         |
| Unstable angina                       | 37 (5.12%)   | 32 (5.00%)       | 5 (6.02%)     |         |
| Q-wave AMI                            | 387 (53.5%)  | 344 (53.8%)      | 43 (51.8%)    |         |

Data are presented as the n (%) or the median [25th percentile; 75th percentile]. CVE, cardiovascular event; ACS, acute coronary syndrome; bpm, beats per minute; and AMI, acute myocardial infarction. Significant p values (p < 0.05) are presented in bold.

In the same way, HypnoLaus subjects were described using sociodemographic and clinical characteristics by tertiles of the two RP components (Supplementary Table 8). Subjects with high adherence in component 1 had more comorbidities, as third tertile showed a greater proportion of subjects with hypertension, diabetes, dyslipidemia and a higher body mass index (BMI). In component 2, the third tertile showed a greater proportion of subjects with hypertension, a lower proportion of subjects with dyslipidemia and no differences regarding BMI and diabetes.

**Relationship Between Respiratory Polygraphy Components and Recurrent Cardiovascular Risk**

In the present study, from the ISAACC study, we explored specific RP parameters and components...
In the subgroup of patients without previous ACS, OSA severity (measured by AHI) showed a trend toward statistical association [HR (95% CI) of 1.62 (0.98–2.66)] with an increased risk of recurrent cardiovascular events (Supplementary Table 10).

In the analysis of RP components and the risk of recurrent cardiovascular events, it was observed that component 2 showed a significant independent association with the risk of recurrent
TABLE 2 | Description of the respiratory polygraphy parameters by tertiles of the components derived from the PCA in the ISAACC cohort.

| Component 1 | Component 2 |
|-------------|-------------|
| **RP parameters** | **p for trend** | **RP parameters** | **p for trend** |
| | 1st tertile | 2nd tertile | 3rd tertile | (N = 239) | (N = 238) | (N = 246) | (N = 239) | (N = 238) | (N = 246) | (N = 239) | (N = 238) | (N = 246) |
| AHI, events per h | 6 [8.6] | 18 [18] | 35.2 [31.5] | 0.001 | 5.2 [11.7] | 15.8 [17.2] | 32.8 [26.3] | 0.001 |
| ODI > 4%, per h | 4.2 [5.9] | 15.1 [13.8] | 32.9 [30.9] | 0.001 | 4 [11.6] | 13 [16.7] | 27.6 [25.4] | 0.001 |
| Mean SaO₂, % | 94.3 [1.9] | 93.2 [1.7] | 91.8 [2.9] | 0.001 | 92.2 [3.7] | 93 [3] | 94 [2] | 0.001 |
| Minimum SaO₂, % | 89 [4] | 86 [4] | 80 [8.8] | 0.001 | 85 [8] | 86 [6] | 85.5 [6] | 0.312 |
| Average duration of events, sec | 19 [7] | 20 [6] | 20 [7.8] | 0.001 | 17 [6] | 20 [6] | 22 [8] | 0.001 |
| Time with SaO₂ < 90%, % | 0 [0.3] | 0.8 [2.2] | 13 [29.3] | 0.001 | 3.1 [33.4] | 0.8 [5.1] | 0.9 [3.8] | 0.001 |

Data are presented as the median [IQR (interquartile range)]. PCA, principal component analysis; RP, respiratory polygraphy; AHI, apnea-hypopnea index; ODI, oxygen desaturation index; and SaO₂, oxygen saturation. The p value for trend was calculated using Spearman’s rank correlation coefficient. Significant p values (p < 0.05) are presented in bold.

CARDIOVASCULAR EVENTS IN PATIENTS WITH THE HIGHEST ADHERENCE (3RD TERTILE) OF COMPONENT 2 WITH AN ADJUSTED HR (95% CI) OF 2.44 (1.07 to 5.56). FOR COMPONENT 1, NO SIGNIFICANT CONTRIBUTION WAS FOUND TO THE RISK OF RECURRENT CARDIOVASCULAR EVENTS (TABLE 3 AND FIGURE 3). THE DISCRIMINATORY POWER OF THE MODELS SHOWED A C-STATISTIC FOR THE RISK OF RECURRENT CARDIOVASCULAR EVENTS OF 72.3% FOR PATIENTS WITHOUT PREVIOUS CVD. SIMILAR RESULTS WERE FOUND EXPLORING COMPONENTS FROM PCA AS CONTINUOUS [HR (95%CI): FOR COMPONENT 2: 1.38 (0.99–1.94) AND FOR COMPONENT 1: 0.82 (0.6–1.13)].

IN THE HYPNOlaus COHORT THE RISK OF RECURRENT CARDIOVASCULAR EVENT IN PATIENTS WITH FIRST ACS CANNOT BE ASSESSED DUE TO ITS POPULATION-BASED DESIGN.

DISCUSSION

IN THE PRESENT STUDY, WE EXPLORATED THE RELATIONSHIP BETWEEN SPECIFIC COMPONENTS OF SLEEP-DISORDERED BREATHING AND THE RISK OF RECURRENT CARDIOVASCULAR EVENTS IN A COHORT OF PATIENTS WITH A FIRST ACS AND WITHOUT PREVIOUS CVD. RECENTLY, IT HAS BEEN REPORTED THAT PATIENTS WITH OSA ADMITTED BY A FIRST ACS WITHOUT PREVIOUS CVD PRESENT AN INCREASED RISK OF RECURRENT CARDIOVASCULAR EVENTS (13). THE RESULTS OF THIS STUDY SHOW AN ASSOCIATION BETWEEN A SPECIFIC POLYGRAPHY COMPONENT AND THE RISK OF RECURRENT CARDIOVASCULAR EVENTS. IN THE ISAACC POPULATION, WE REPORT THAT A POLYGRAPHY COMPONENT MAINLY CHARACTERIZED BY INTERMITTENT HYPOXEMIA (COMPONENT 2) INCREASES THE RISK OF RECURRENT CARDIOVASCULAR EVENTS IN PATIENTS WITH ACS AND WITHOUT PREVIOUS CVD. BASED ON PREVIOUSLY DESCRIBED CARDIOVASCULAR RISK VARIABLES, THE C-STATISTIC FOR THE RISK OF RECURRENT CARDIOVASCULAR EVENTS WAS 72% FOR BOTH PHENOTYPES OF PATIENTS, SIMILAR TO OTHER STUDIES (23). REMARKABLY, THE RP COMPONENTS IDENTIFIED IN THE ISAACC COHORT WERE ALSO IDENTIFIED IN THE HYPNOlaus POPULATION-BASED COHORT.

CURRENTLY, OSA SEVERITY IS CHARACTERIZED BY THE AHI, WHICH CAPTURES ONLY ONE ASPECT OF THIS HETEROGENEOUS DISEASE. THE ABILITY TO DISSECT OSA HETEROGENEITY USING ADDITIONAL FEATURES IS NECESSARY FOR INCORPORATING PERSONALIZED APPROACHES IN DISEASE MANAGEMENT. IN OUR STUDY, WE OBSERVED THAT THE EFFECT OF OSA SEVERITY, ASSESSED ONLY BY THE AHI, SHOWED A TRENDS TOWARD A STATISTICAL ASSOCIATION (WITH AN HR OF 1.62) WITH THE RISK OF RECURRENT CARDIOVASCULAR EVENTS IN THE GROUP OF PATIENTS WITHOUT PREVIOUS CVD. WHEN CONSIDERING THE RP COMPONENTS, WE OBSERVED AN HR OF 2.44 FOR COMPONENT 2, INDICATING AN INCREASE IN THE RISK OF RECURRENT CARDIOVASCULAR EVENTS. BASED ON THE RESULTS, WE SUGGEST THAT THE ANALYSIS OF OTHER PARAMETERS FROM RP COULD CONTRIBUTE TO THE DETERMINATION OF RP COMPONENTS AND THEIR RELATIONSHIP WITH THE DEVELOPMENT OF RECURRENT CARDIOVASCULAR EVENTS IN PATIENTS WHO HAVE SUFFERED AN ACS.

THE ISAACC STUDY (8) AND OTHERS (12) HAVE FAILED TO DEMONSTRATE THE RELATIONSHIP BETWEEN THE AHI AND AN INCREASED RISK OF RECURRENT CARDIOVASCULAR EVENTS. PREVIOUS STUDIES HAVE SUGGESTED THAT OTHER COMPONENTS FROM SLEEP STUDIES COULD CONTRIBUTE TO CHARACTERIZING THE UNDERLYING PATHOLOGY OF OSA.

TABLE 3 | Cox proportional hazard model for the primary composite endpoint in the ISAACC cohort.

| Component 1 | Component 2 |
|-------------|-------------|
| **HR** (95% CI) | p value | p for trend |
| 1st tertile | 1 | 0.49 |
| 2nd tertile | 0.81 (0.41–1.59) | 0.544 |
| 3rd tertile | 0.74 (0.31–1.73) | 0.481 |
| **Component 2** | | |
| 1st tertile | 1 | 0.03 |
| 2nd tertile | 1.58 (0.79–3.17) | 0.194 |
| 3rd tertile | 2.44 (1.07–5.58) | 0.034 |

HR (95% CI), hazard ratio (95% confidence interval). All variables included in the model met the assumptions for proportional hazards. The p value for trend was computed by treating component variables coded as numbers in the model. Significant p values (p < 0.05) are presented in bold.

*Adjusted for age, sex, smoking, alcohol consumption, obesity, hypertension, stroke, diabetes, the severity of ACS, dyslipidemia, antihypertensive drugs, antplatelet and antithrombotic drugs, heart rate, systolic blood pressure, creatinine, stents implanted, cardiovascular event type, troponin peak, and mean SaO₂.
and its association with the risk of CVD. Azarbarzin et al. (12) recently reported that CVD mortality was not associated with the AHI when it was assessed as an independent predictor. In contrast, they found that the hypoxic burden, an estimation of the depth and duration of respiratory-related desaturation, is an alternative metric associated with an increased risk of CVD mortality. Nevertheless, the authors of that study admit that this measure does not fully characterize the components of hypoxic stress because it does not distinguish short and deep desaturations from long and shallow desaturations. In fact, in our study, we found that the component associated with recurrent cardiovascular events was component 2. The highest adherence to this component (3rd tertile), showing the highest risk of recurrent cardiovascular events, was characterized by higher AHI, higher mean SaO\textsubscript{2} and longer event duration. This tertile would suggest an intermittent hypoxemia component. In contrast, the lowest adherence to this component was characterized by lower AHI, ODI and mean SaO\textsubscript{2}, which would suggest a sustained hypoxemia component.

The results of the present study suggest that from available variables from RP, it is possible to improve the evaluation of the risk of recurrent cardiovascular events with an HR of 1.61 exclusively with AHI to 2.44 considering additional variables. The patients with the highest adherence to component 2 (3rd tertile), which represents an intermittent hypoxemia component, strengthen the hypothesis that OSA exerts a risk in specific subgroups of patients with ACS. In contrast, the patients with the lowest adherence to this component, characterized by sustained hypoxemia, would have a lower risk of recurrence of a cardiovascular event. Notably, the same RP components were found in the HypnoLaus cohort suggesting that these components are not specific to the ISAACC population. However, it was not possible to estimate the predictive nature of the identified RP components for recurrent cardiovascular events in this cohort. Since, the low number of available cardiovascular events due to its population-based design.

The existence of specific RP components that could be associated with detrimental effects in specific phenotypes of patients with ACS invites us to reconsider the design strategies of new interventional studies to demonstrate the possible beneficial effect of CPAP treatment on secondary CVD prevention. These preliminary results raise the possibility that, in studies such as the ISAACC study (8), no beneficial effect was seen because of the inclusion of patients with different phenotypes of ACS where OSA could have different effects.

The strengths of our study include its multicenter design with a large population of patients with diagnoses of ACS and OSA. In this study, all participating centers from the ISAACC study used the same methodology, and the sleep study was performed with the same polygraph model. In addition, the RP components identified in the ISAACC cohort were validated in the HypnoLaus population-based cohort. The study presents some limitations that deserve mention. First, to identify specific RP components, a PCA analysis was performed using six RP parameters, including the AHI, ODI, mean and minimum SaO\textsubscript{2}, average duration of events and percentage of time with SaO\textsubscript{2} < 90%. The usefulness of other variables such as the mean respiratory rate as a predictor of cardiovascular recurrence was previously reported. This variable was not available in the ISAACC study, and future studies exploring the contribution of this specific variable as a predictor of cardiovascular outcomes should be performed. Second, the results of this study indicate the possibility of identifying RP components associated with different risks of recurrent cardiovascular events in patients who have suffered a first ACS and without previous CVD. However, these exploratory
results should be validated in future independent cohorts. Third, in our study, we determined RP components using RP parameters that do not include information about sleep phases. Some studies have suggested that rapid eye movement-related respiratory disorders could be informative regarding cardiovascular risk associations with respiratory sleep disorders (24). The contribution of information about sleep phases should be explored in further studies. Finally, the results from the present study may not be extrapolated to a population different from that of patients admitted to the hospital for ACS. This fact makes it necessary to specifically identify phenotypes in patients with OSA who are attended in different clinical settings.

As a conclusion, in patients who have suffered a first ACS and without previous CVD, there exists a specific RP component, mainly characterized by intermittent hypoxemia, that is associated with a greater risk of recurrent cardiovascular events. These first exploratory results must be confirmed in future studies, which will evaluate the effect of RP components of specific ACS populations and the possible beneficial effect of CPAP treatment for patients with a first ACS and without previous CVD, in whom a deleterious effect of this RP component has been found.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

The ethics committee of each participating center approved the study (approval number in the coordinating center: 2010-852) and patients provided written informed consent. The patients/participants provided their written informed consent to participate in this study.

MEMBERS OF THE SPANISH SLEEP NETWORK

Laura Abad, Aida Munoz, Elisabet Zamora, Ignacio Vicente, Sandra Ingleis, Carlos Egea, Jaime Marcos, Almudena Fernández, Valentín Cabriada-Nuño, Sonia Castro, Leyre Serrano, Marina Floreis, Anna Mas, Maricel Arbones, Silvia Ortega, Alicia Martín, Jose Miguel Romain-Sainchez, Ma Isabel Valiente-Diaz, Ma Esther Viejo-Ayuso, Concepcioin Rodriguez-García, Laura Vigil, Enriqueta Ramirez, Marilia Pinjar, Elisabet Martínez, Blanca Barriuso, Jaime Corral, Francisco Javier Goimez de Terreros Caro, Antonia Barceloi, Paloma Giménez, Ana Ma Fortuna, Patricia Penhacoba, Abel Jesus Martínez-Garcia, Sergio García-Castillo, Lara Navas, Oininta Garmenda, Josei Sancho, Salvador Perelloi, Gemma Rubinois, and Rocio Gallego.

AUTHOR CONTRIBUTIONS

AZ, GS, AS-d-l-T, EG-L, IB, FB, RH, and MS-d-l-T contributed to the study concept and design. GS, AS-d-l-T, GT, JD, JA, JD-C, AU, OMe, MJM, EO-C, JFM, MDP, MM, RC, JMM, EC, OMi, LP, AC, DM, RM, and RH contributed to the data acquisition. AZ, GS, AS-d-l-T, EG-L, IB, GT, FB, RH, and MS-d-l-T contributed to the data analysis and interpretation. All authors contributed to the drafting of the manuscript, critically revised the manuscript for important intellectual content and approved the final version. MS-d-l-T is the guarantor of the manuscript.

FUNDING

Instituto de Salud Carlos III (ISCIII; PI10/02763, PI10/02745, PI18/00449, and PI19/00907), co-funded by FEDER, “Una manera de hacer Europa,” IRBLleida – Fundació Pifarré, CERCA Programme/Generalitat de Catalunya, SEPAR, ResMed Ltd. (Australia), Esteve-Teijin (Spain), Oxigen Salud (Spain), Associació Lleidatana de Respiratori (ALLER), and Sociedad Española de Sueño (SES). AZ is the recipient of a predoctoral fellowship “Ajuts 2021 de Promoció de la Recerca en Salut-9a edició” from IRBLleida/Diputació de Lleida. JD acknowledges receiving financial support from ISCIII (Miguel Servet 2019: CP19/00108), co-funded by the European Social Fund (ESF), “Investing in your future.” MS-d-l-T has received financial support from a “Ramón y Cajal” grant (RYC2019-027831-I) from the “Ministerio de Ciencia e Innovación – Agencia Estatal de Investigación” co-funded by the European Social Fund (ESF)/“Investing in your future.” FB received funding from from ResMed (an Australian company that develops products related to sleep apnea), the Health Research Fund, the Spanish Ministry of Health, the Spanish Respiratory Society, the Catalanian Cardiology Society, Esteve-Teijin (Spain), Oxigen Salud (Spain), and ALLER. The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication.

ACKNOWLEDGMENTS

We thank the individuals who participated in this trial and their families, the clinical and research teams of the various sleep and cardiology departments, and the Spanish Sleep Network for their work on the ISAACC study.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2022.870906/full#supplementary-material
REFERENCES

1. Kumar A, Cannon CP. Acute coronary syndromes: diagnosis and management, part I. Mayo Clin Proc. (2009) 84:917–38. doi: 10.4065/84.10.917

2. Florés M, De Batlle J, Sánchez-De-La-Torre A, Sánchez-De-La-Torre M, Aldomá A, Worner F, et al. Central sleep apnoea is related to the severity and short-term prognosis of acute coronary syndrome. PLoS One. (2016) 11:e0167031. doi: 10.1371/journal.pone.0167031

3. Heinzer R, Vat S, Marques-Vidal P, Martí-Soler H, Andries D, Tobback N, et al. Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study. Lancet Respir Med. (2015) 3:310–8. doi: 10.1016/S2213-2600(15)00043-0

4. Nakashima H, Kurobe M, Minami K, Furudono S, Uchida Y, Amenomori K, et al. Effects of moderate-to-severe obstructive sleep apnoea on the clinical manifestations of plaque vulnerability and the progression of coronary atherosclerosis in patients with acute coronary syndrome. Eur Hear J Acute Cardiovasc Care. (2015) 4:75–84. doi: 10.1177/2048872614530865

5. Mediano O, Cano-Pumarega I, Sánchez-de-la-Torre M, Alonso-Álvarez ML, Troncoso MF, García-Río F, et al. Upcoming scenarios for the comprehensive management of obstructive sleep apnea: an overview of the spanish sleep network. Arch Bronconeumol. (2020) 56:35–41. doi: 10.1016/j.arbres.2019.05.017

6. Sánchez-de-la-Torre M, Campos-Rodríguez F, Barbé F. Obstructive sleep apnoea and cardiovascular disease. Lancet Respir Med. (2013) 1:61–72. doi: 10.1016/S2213-2600(12)70051-6

7. Marin JM, Carrizo SJ, Vicente E, Agustí AGN. Long-term cardiovascular outcomes in men with obstructive sleep apnea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet. (2005) 365:1046–53. doi: 10.1016/S0140-6736(05)74229-X

8. Sánchez-de-la-Torre M, Sánchez-de-la-Torre A, Bertran S, Abad J, Duran-Cantolla J, Cabriada V, et al. Effect of obstructive sleep apnoea and its treatment with continuous positive airway pressure on the prevalence of cardiovascular events in patients with acute coronary syndrome (ISACC study): a randomised controlled trial. Lancet Respir Med. (2019) 7:359–67. doi: 10.1016/S2213-2600(19)30271-1

9. Zapater A, Sánchez-de-la-Torre M, Benítez ID, Targa A, Bertran S, Torres G, et al. The effect of sleep apnea on cardiovascular events in different acute coronary syndrome phenotypes. Am J Respir Crit Care Med. (2020) 202:1698–706. doi: 10.1164/rccm.202004-1127OC

10. Péker Y, Glantz H, Eulnerburg C, Wegscheider K, Herlitz J, Thunström E. Frontiers in Medicine | www.frontiersin.org 10 June 2022 | Volume 9 | Article 870906

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zapater, Solelhac, Sánchez-de-la-Torre, Gracia-Lavedan, Benitez, Torres, De Batlle, Haba-Rubio, Berger, Abad, Duran-Cantolla, Urrutia, Mediano, Masdeu, Ordax-Carbayo, Masa, De la Peña, Mayos, Coloma, Montserrat, Chiner, Mingué, Pascual, Cortijo, Martínez, Dalmau, Lee, McEvoy, Barbé, Heinzer and Sánchez-de-la-Torre. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.